Ventrolateral periaqueductal gray matter integrative system of defense and antinociception

Gustavo Henrique de Mello Rosa1 · Farhad Ullah2 · Yara Bezerra de Paiva1 · Juliana Almeida da Silva1 · Luiz Guilherme S. Branco3 · Alexandre Pinto Corrado1 · Priscila Medeiros1,4 · Norberto Cysne Coimbra1,5 · Audrey Franceschi Biagioni1,6

Received: 14 July 2021 / Revised: 8 February 2022 / Accepted: 9 February 2022 / Published online: 24 February 2022 © The Author(s) 2022

Abstract
Defensive responses are neurophysiological processes crucial for survival during threatening situations. Defensive immobility is a common adaptive response, in rodents, elaborated by ventrolateral periaqueductal gray matter (vlPAG) when threat is unavoidable. It is associated with somatosensory and autonomic reactions such as alteration in the sensation of pain and rate of respiration. In this study, defensive immobility was assessed by chemical stimulation of vlPAG with different doses of NMDA (0.1, 0.3, and 0.6 nmol). After elicitation of defensive immobility, antinociceptive and respiratory response tests were also performed. Results revealed that defensive immobility was followed by a decrease in the nociceptive perception. Furthermore, the lowest dose of NMDA induced antinociceptive response without eliciting defensive immobility. During defensive immobility, respiratory responses were also disturbed. Interestingly, respiratory rate was increased and interspersed with prolonged expiratory phase of breathing. These findings suggest that vlPAG integrates three different defensive behavioral responses, contributing to the most effective defensive strategies during threatening situations.

Keywords Defensive immobility · Antinociception · Respiratory function · Ventrolateral column of periaqueductal gray matter

Abbreviations
vlPAG Ventrolateral column of periaqueductal gray matter

Introduction
Threatening situations are known to influence defensive behavioral reaction patterns, causing motor and autonomic response expressions to enhance the survival probabilities [14, 20]. Ethological studies emphasizing unconditioned fear showed that different threatening
contexts elicit different defensive behavioral strategies [5, 11]. For instance, unavoidable fear stimuli lead to immobility defensive reaction in rodents, characterized by a tense posture and entire body immobility, except breathing movement which can be visualized [6, 9]. The defensive state has been reported to be organized by the ventrolateral periaqueductal gray matter (vlPAG) column [4, 51]. The same nuclei have been also reported to integrate autonomic and sensory information that accompanies defensive behavior [29, 32, 49]. Defensive immobility organized by the vlPAG neurons have been described during several conditions such as contextual fear conditioning [8, 45], prey versus predator paradigm [10], and midbrain tectum electrical and chemical stimulation [47, 48]. Despite the well-reported pre-escape and after-escape defensive immobility elaborated by the periaqueductal gray matter (PAG), the associative somatosensory and autonomic reactions such as pain sensation and respiratory rate organized by vlPAG are not well known yet.

Enhanced sensory processing is suggested to optimize defensive strategy during an inescapable predator encounter [19, 46]. When a prey faces a threat, the neural circuits of fear inhibit the somatosensory system, resulting in defensive behavior and antinociception [27, 30, 31]. After antinociceptive pathways are activated, the injured prey is able to focus on defensive behavior performance instead of pain-related recuperative behavior, which increases the chances of survival [7, 46]. During inescapable threat, the integrated defensive immobility and antinociceptive responses produced by the activation of the vlPAG neurons were observed to occur simultaneously [29]. However, some studies suggest that there is no pharmacological relationship between these two responses. It has been examined that defensive antinociception can be reversed by opioid and serotoninergic antagonist local treatments; however, these treatments showed no effect on the defensive behavioral responses elaborated by the vlPAG neurons [16]. In order to determine whether defensive immobility and defensive antinociception are mutually dependent or not, we treated vlPAG with different doses of N-methyl-D-aspartic acid (NMDA) and examined its effect in eliciting defensive immobility and antinociceptive responses.

Furthermore, the contribution of vlPAG in respiratory control associated with defensive strategies was also currently analyzed. In fact, it has been proposed that PAG may link both defensive immobility and changes in breathing rate [44]. Here, we examined the pattern of defensive immobility behavior produced by vlPAG after its chemical stimulation and its relationship with defensive antinociception and respiratory processes, which are crucial for the survival of prey during threatening situations.

**Methods**

**Ethical approval**

The experiments were carried out according to the ethical principles developed by the Ethics Committee on Animal Experimentation of FMRP-USP (CETEA), which are in accordance with the ethical principles National Commission on Ethics in Animal Experimentation (CONCEA) protocol on registration 96/2010.

**Animals**

Male Wistar rats (*Rattus norvegicus*, Rodentia, Muridae), weighing 250–300 g (n = 8 per group), were used in these behavioral experiments. The enclosure was maintained at 21 ± 2 °C on a light–dark cycle. Lights were on from 7 a.m. to 7 p.m. Animals were housed in groups of four in acrylic cages (41 × 34 cm) and were given free access to food and water throughout the experiment. Psychobiological experiments were performed between 9 a.m. and 4 p.m. Surgeries of all rats were performed under deep anesthesia. Every experimental procedure was planned to minimize the suffering of animals and to decrease the number of animals used in the experiment.

**Drugs**

N-methyl-D-aspartic acid (NMDA; Sigma-Aldrich, St. Louis, USA) was used to stimulate the midbrain. Different doses of NMDA (0.1, 0.3, and 0.6 nmol) were injected in the vlPAG. The vehicle (0.9% NaCl) was also used as a control. All injections were performed in a volume of 0.2 µL.

**Stereotaxic surgery**

The animals were deeply anaesthetized with intramuscular injections of ketamine in a dose of 100 mg/kg and xylazine in a dose of 10 mg/kg. After anesthesia, the head of each animal was fixed in a stereotaxic frame (David Kopf, Tujunga, CA, USA). Stainless steel guide cannulas were implanted in the midbrain 1 mm above the vlPAG with the following coordinates, considering bregma as a reference: antero-posterior = −7.8 mm, middle-lateral = 0.8 mm, and dorso-ventral = 6.4 mm, in an angle of 20°, according to the rat brain in stereotaxic coordinate atlas [38]. Stereotaxic placement of guide cannulas was angled to avoid damage and bleeding from the superior sagittal sinus [17]. Five
days later, rats received a random treatment into vlPAG of either physiological saline or NMDA delivered by a needle (0.3 mm of outer diameter) linked to a syringe (Hamilton) through a polyethylene tube. The microinjection needle was inserted through the guide-cannula until it reached the vlPAG (1 mm below the guide-cannula). Injections occurred over a 40-s period. Only rats that received microinjection within the vlPAG were included in the present study. At the end of the surgery, each animal received an intramuscular injection of benzathine penicillin G (120,000 IU; 0.1 mL) and a subcutaneous injection of the non-steroidal analgesic and anti-inflammatory meglumine flunixin (2.5 mg/kg).

### Experimental procedures

#### Behavioral testing

The behavioral tests were carried out in a circular arena (50 cm wide × 60 cm high) with transparent acrylic walls, located in a lighted experimental room (350 lx at the arena floor level). The circular arena floor was divided into 12 equal sections used to count crossings. Defensive immobility behavior was defined as absence of body movements for 6 s, except respiratory movements. The frequency and duration of this behavior was recorded, during 5 min, immediately after rats received a single microinjection of either physiological saline or NMDA in the mesencephalic tegmentum.

#### Antinociceptive testing

The rats had their nociception thresholds compared using the tail-flick test. Each animal was placed in a restraining apparatus (Insight, Ribeirão Preto, Brazil) with acrylic walls, and its tail was placed on a heating coil (tail-flick Analgesia Instrument; Insight, Ribeirão Preto, Brazil). The amount of heat applied to the tail was increased until the animal removed its tail from the apparatus. The coil (Ni/Cr alloy; 26.04 cm in length × 0.02 cm in diameter) began at room temperature (approximately 20 °C), and then current was applied to increase the temperature of the coil at a rate of 9 °C/s [2, 15, 18, 28]. If necessary, small adjustments were made to the intensity of the current at the beginning of the experiment to obtain three consecutive tail-flick latencies (TFL) between 2.5 and 3.5 s. If the animal did not remove its tail from the heater within 6 s, the apparatus was turned off to prevent damage to the skin. Three baseline measurements of control TFL were taken at 5-min intervals. TFL measured every 5 min for 30 min (1st, 2nd, 3rd, 4th, 5th, 6th, and 7th tail withdrawal measurement) were taken 1 min after end of the defensive behavior assay.

### Measurements of pulmonary ventilation

Respiratory frequency ($f_R$), tidal volume ($V_T$), and consequently ventilation ($V_e$) were obtained using the barometric method (whole-body plethysmography (WBP)) according to Bartlett and Tenney [1] and Malan [33] and used in previous studies [40, 41]. In brief, rats were housed fully conscious and unrestrained within the WBP (manufactured by Precision Workshops Section, University of São Paulo, Ribeirão Preto) chamber, which consist of a plexiglas square box (30 × 30 × 30 cm). Chamber was used in a closed mode to allow the WBP assessment. Therefore, the inlet and the outlet of the chamber were closed by a luer lock connector or a three-position valve, respectively. Air flow was stopped and the chamber remained completely sealed during the performance of each ventilation measurement. The calibration volume was performed with a known volume of air (1 mL) injected by an insulin syringe into the chamber. Respiratory functions were estimated considering the chamber pressure changes which were captured by a pressure transducer and digitization (PowerLab DAQ) was performed with an analog–digital interface (PowerLab 8/35; ADInstruments) and LabChart software (ADInstruments). Two respiratory variables were measured, $f_R$ and $V_T$, the last calculated through the formula: $V_T = P_IP_k × V_k × T_c/T_R × (P_B - P_C)/(P_B - P_k) × T_c/T_k × (P_B - P_k)$, where $V_k$ is the calibration volume, $P_T$ is the pressure deflection associated with each volume of tidal air, $P_k$ is the pressure deflection associated with each volume of air injected for calibration, and $T_p$ is the body temperature. Also, $T_r$ is the room temperature, $T_c$ is the air temperature inside the chamber, $P_B$ is the pressure barometric, $P_C$ is the water vapor pressure at body temperature, and $P_k$ is the pressure of water vapor at chamber temperature. $V_e$ was measured by the product of $f_R$ by $V_T$. Body temperature ($T_b$) was measured using temperature sensors (data loggers; DLs; SubCue) implanted intraperitoneally, on the same day of the stereotaxic surgery. DLs were previously programmed to acquire data every 5 min. The DLs were removed and the data were downloaded using specific software (SubCue, Calgary, Canada).

### Experimental design

Animals were submitted to surgical procedure to implant a guide cannula targeting the vlPAG. Rats were allowed to recover from surgery for a period of 5 days. The experiment consisted of 2 procedures, on successive days. First day, nociceptive thresholds of rats were measured to determine the baseline after a habituation period of 10 min. Then, rats were gently wrapped in a cloth and hand held while they received a random treatment into the vlPAG of either physiological saline or a single dose of NMDA. Immediately after the microinjection procedure, rats were placed in the open...
field apparatus and behavioral response was recorded during 5 min. After 1 min, nociceptive responses (TFL) were measured every 5 min during 30 min. Second day, the pulmonary ventilation was evaluated in the whole-body plethysmograph chamber in the same group of animals. After a habituation period of 30 min, three baseline measurements of pulmonary function were recorded at 5-min intervals. Subsequently, rats were submitted again to the microinjection procedure while they were inside the plethysmography chamber. Animals received the same treatment of the day before that is either saline or the same dose of NMDA. Immediately after, pulmonary measurements were evaluated during 5 min with an interval of 1 min. During the interval, the chamber was kept open for the entry of atmospheric air. For each respiratory function recording, events were collected and an average of 20-s recording was analyzed starting immediately after the microinjection, and other two recording events with the same events pattern were analyzed (Phase 1). Respiratory function was notably interspersed with episodes of expansion of expiratory time, starting approximately 40 s after the microinjection (Phase 2). Recording events from those episodes were also calculated as average of 20-s recording.

Independent groups of rats were also submitted to stereotaxic surgical procedure to implant a guide cannula targeting the vlPAG. Five days later, nociceptive thresholds of rats were measured to determine the baseline a habituation period of 10 min. Then, rats were gently wrapped in a cloth and hand held while they received a random treatment into the vlPAG of either physiological saline or 0.1 µL of NMDA. One minute later, nociceptive responses (TFL) were measured every 5 min during 30 min.

**Histology**

Upon completion of the experiments, each animal was anaesthetized with ketamine at 92 mg/kg (Ketamina®) and xylazine at 9.2 mg/kg (Dopaser®) and perfused through the left cardiac ventricle using an infusion pump (Master Flex® L/S TM, Vernon Hills, IL, USA). The thoracic descending aorta was clamped, the pericardium was removed to allow perfusion through left ventricle, and the blood was washed out with Tyrode’s solution (40 mL at 4 °C). The animal was then perfused with 200 mL ice-cold 4% (w/v) paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.3) for 15 min at a pressure of 50 mmHg. The encephalon was quickly removed and maintained in 4% paraformaldehyde for at least 4 h and was then immersed in a 10% sucrose solution for 48 h. Tissue pieces were immersed in 2-methylbutane (Sigma-Aldrich, St. Louis, USA), frozen on dry ice (30 min), embedded in Tissue-Tek, and cut on a cryostat (CM 1950, Leica, Mannheim, Germany). Slices were then mounted on glass slides that were coated with chrome alum gelatin to prevent detachment and stained in a robotic Autostainer (CV 5030 Leica Autostainer) with hematoxylin–eosin. The sections were viewed under a motorized photomicroscope (AxioImager Z1, Zeiss, Oberkochen, Germany), and the positions of the tips of the guide cannula were localized according to Paxinos and Watson’s stereotaxic atlas [38].

**Statistical analysis**

Data from independent groups of animals submitted to the vlPAG chemical stimulation were checked for normality and homogeneity. Behavioral responses were analyzed using one-way analysis of variance followed by Newman-Keuls posthoc test. For the tail-flick latencies, a repeated measures two-way ANOVA was applied to evaluate the statistical distribution of the data sets. Respiratory response (fR, Vt, and VE) were evaluated by repeated measures two-way ANOVA followed by Bonferroni post hoc test. All values were expressed as mean ± SEM. The p values < 0.05 were considered statistically significant.

**Results**

Midbrain tegmentum chemical stimulation performed with NMDA microinjection in vlPAG induced the defensive behavioral response of defensive immobility, alteration in the nociceptive threshold, and pulmonary ventilation. The position of the cannula was histologically confirmed, and needle tracts were found between bregma – 7.56 mm and – 8.64 mm (Fig. 1). Small variations in the guide-cannula position were found; therefore, only rats with cannula tracks ending 1 mm above the vlPAG area were included in the study.

The vlPAG treatment with NMDA at 0.3 nmol and 0.6 nmol caused increase in the frequency [F (3,28) = 61.45; p < 0.001] and in the duration [F (3,28) = 98.24; p < 0.001] of defensive immobility response compared to the groups treated with physiological saline and NMDA at the lowest dose (0.1 nmol), as shown in Fig. 2. The effect of NMDA treatment was also observed in the locomotor activity expressed by the number of crossing [F (3,28) = 43.30; p < 0.001] compared to the groups treated with physiological saline and NMDA at 0.1 nmol (Fig. 2).

Defensive immobility elicited by chemical stimulation of vlPAG with NMDA was followed by defensive antinociception recorded during 5 min after the defensive response. According to the repeated measures two-way ANOVA, there was a statistically significant effect of treatment [F (3,28) = 5.6; p < 0.01], of time [F (7,22) = 9.34; p < 0.001], and of treatment versus time interaction [F (21,62) = 7.21; p < 0.001]. The vlPAG chemical stimulation with NMDA at 0.3 nmol and 0.6 nmol increased the tail-flick latencies [F
(3.28) = 12.75; p < 0.001] in comparison to the control group and to the group treated with NMDA at the lowest dose of 0.1 nmol (Fig. 3).

The microinjection of NMDA in vlPAG caused a dynamic change in respiratory responses characterized by a period of increase in the respiratory frequency (Phase 1; Fig. 4A) interspersed with episodes of prolonged expiratory phase of breathing (Phase 2; Fig. 4B). There was a statistically significant effect of treatment [$F (1,27) = 127.8; p < 0.001$ and $F (1,27) = 15.46; p < 0.001$], time [$F (3,27) = 33.86; p < 0.001$], and treatment versus time interaction [$F (3,27) = 32.91; p < 0.001$ and $F (3,27) = 21.7; p < 0.001$] on $f_R$, regarding the Phase 1 and 2, respectively. For $V_T$ there was a statistically significant effect on treatment [$F (1,27) = 7.69; p < 0.01$ and $F (1,27) = 60.88; p < 0.001$], time [$F (3,27) = 7.23; p < 0.01$ and $F (3,27) = 39.56; p < 0.001$], and the treatment versus time interaction [$F (3,27) = 2.7; p > 0.05$ and $F (3,27) = 26.16; p < 0.001$] regarding the Phase 1 and 2, respectively. Considering the $V_E$, there was a statistically significant effect of treatment [$F (1,27) = 30.34; p < 0.001$ and $F (1,27) = 5.38; p < 0.05$], of time [$F (3,27) = 20.97; p < 0.001$ and $F (3,27) = 6.27; p < 0.01$], and of treatment versus time interaction [$F (3,27) = 9.18; p < 0.001$ and $F (3,27) = 2.3; p > 0.05$] in the Phase 1 and 2, respectively. vlPAG activation caused an initial increase in the $f_R$, $V_T$, and $V_E$ after the intramesencephalic injection of NMDA in a dose of 0.6 nmol ($p < 0.001$) compared to all other groups (Fig. 5A). Those responses were interspersed with a decrease in the $f_R$ ($p < 0.001$ and prolonged expiratory phase increasing the $V_T$ ($p < 0.001$) and $V_E$ ($p < 0.001$) compared to control group, and to NMDA (0.1 nmol and 0.3 nmol)-treated groups (Fig. 4B). vlPAG treatment with NMDA at 0.3 nmol also caused a dynamic change in respiratory responses with a significant increase in the $f_R$ ($p < 0.001$) with no significant
effect on $V_T$ and $V_E$ (Phase 1), followed by increase in the $V_T$ ($p < 0.001$) and without changes in the basal $f_R$ and $V_E$ compared to control and to vlPAG stimulation with NMDA in a dose of 0.1 nmol (Fig. 4 A and B, respectively).

In order to evaluate the effect of small dose of NMDA in the nociceptive threshold, independent groups of animals were submitted to the tail-flick test immediately after the intrame-

encephalic microinjection of the excitatory amino acid. vlPAG chemical stimulation elicited antinociception up to 5 min, which is in line with time of effect of NMDA at 0.3 and 0.6 evaluated in behavioral and respiratory responses. According to the repeated measures two-way ANOVA, there was significant effects of treatment [$F(1.14)=24.55; p < 0.001$], of time [$F(7.8)=16.55; p < 0.001$], and of treatment versus time interaction [$F(7.8)=11.72; p < 0.001$]. Chemical stimulation of vlPAG with NMDA at the lowest dose (0.1 nmol) increased the tail-flick latencies [$F(1.14)=50.4; p < 0.001$] when compared to the physiological saline-treated control group (Fig. 5).
**Discussion**

Defensive immobility response, characterized by cessation of voluntary movements, was observed in the present study after the NMDA microinjection in the vlPAG. The pronounced effects of electrical and chemical stimulations of the ventrolateral portion of PAG in eliciting immobility are well established [4, 34, 48, 50]. Our findings indicate that vlPAG neuronal circuits integrate defensive behavioral responses, sensory, and autonomic reactions. Consistently with a previous report [4], we demonstrated that the chemical stimulation of this mesencephalic region induces a defensive immobility response in a dose-dependent manner. Moreover, the activation of the excitatory glutamnergic receptors of the vlPAG also inhibits pain perception and elicits respiratory changes, representing the unconditioned fear-induced antinociception displayed by laboratory animals and also chemical stimulation of dorsal columns of the PAG [13], and by those threatened by a natural predator [14].

We also observed that intermediate and high doses of NMDA microinjected into vlPAG significantly increased the nociceptive threshold, evaluated after the defensive immobility response. The integrative systems of defensive behavior and attenuation of pain-related responses lead to the optimal strategy for survival [14]. The perceptual-defensive-re recuperative theory proposed by Bolles and Fanselow [7] suggests that fear inhibits pain, facilitating the perception of danger instead of recuperative responses that might compromise the animal survival. Interestingly, the treatment of vlPAG with low dose of NMDA activated antinociceptive process without eliciting defensive immobility response. It suggests that vlPAG-elaborated antinociception and behavioral responses can occur independently. We can only speculate that antinociceptive process, observed promptly after NMDA (0.1 nmol) vlPAG treatment, is induced by the local action of the NMDA in the vlPAG neurons. On the other hand, the antinociception that follows the behavioral defensive responses may be related to the activation of the entire circuit underlying fear [3, 14]. In fact, time of effect of NMDA into the vlPAG lasts approximately 5 min [36], as observed in the tail-flick test immediately after the injections of 0.1 nmol NMDA and after 0.3- and 0.6-nmol treatment evaluated in behavioral and respiratory responses. Altogether, these results are consistent with the hypothesis that nociceptive reflexes and immobility may not occur simultaneously [35]. Despite the fact that both freezing and antinociception are coordinated by vlPAG GABA-benzodiazepine mechanisms [16], distinct neuronal pathway of the ventrolateral periaqueductal gray is likely to contribute to fear-related defensive behavior, integrating sensory and motor mechanisms.

In addition to the well-evidenced behavioral repertoire organized by vlPAG, it was observed in the present study that chemical stimulation of vlPAG induced irregular breathing pattern. The caudal part of vlPAG plays key role in controlling the spontaneous breathing pattern [43] whose activation triggers dysfunctional reactions related to anxiety disorder [25]. In the present study, we observed dysfunction in the respiratory responses during the expression of defensive immobility. The increased respiratory frequency and pulmonary ventilation were interspersed with episodes of reduction in respiratory frequency and prolonged expiratory phase of breathing, which is considered an adaptive response crucial for defensive immobility performance when a threat is imminent [39]. It is previously suggested that
vlPAG stimulation evokes irregular tachypnea characterized by increase in the respiratory frequency followed by its decrease along with episodes of apnea [42–44]. Despite the fact that we did not observe apnea in this study, our results are in line with evidence suggesting that vlPAG coordinates somatomotor mechanisms that are required in the context of basic survival [12]. Indeed, midbrain structures are activated in rodents, threatened by venomous coral snakes in the polygonal arena for snake test [37]. The irregular respiratory responses organized by vlPAG neurons may be under...
the influence of dPAG [26] and IPAG descending projections [43]. In fact, the different columns of PAG have been reported to regulate several respiratory patterns. While dorsal region stimulation causes tachypnea [42], the lateral column promotes inspiratory apneusis and caudal ventrolateral PAG induces irregular breathing in cats [44]. In addition, vlPAG maintains connections with the limbic system and cerebral cortical structures that are crucial for regulating the behavioral response and respiratory functions to promote survival [21, 24]. Respiratory rate is particularly coordinated by the different columns of PAG during the threatening stimulus [22]. It was demonstrated through functional magnetic resonance in humans that PAG lateral columns are activated during conditioned respiratory threat test. On the other hand, the PAG ventrolateral column was activated in the anticipatory phase [22]. In the same study, it is suggested that lateral columns of PAG modulate sensorimotor response during shortness of breath, and the PAG ventrolateral columns participate in the perception of the threat, preventing shortness of breath [42]. Thus, different columns of PAG modulate eupnea according to specific behavioral responses during dangerous situations.

Conclusion

The current study provided novel insights on the organization of such defensive responses that depend on the intensity of the stimulus. In this sense, highest tested dose of NMDA induced defensive immobility behavior, fear-induced antinociception, and tachypnea in a dose-dependent manner. On the other hand, the lowest dose of NMDA was only effective to induce defensive antinociception, probably because the antinociceptive process occurs in a dissociated manner recruiting different neuronal circuits, such as opioid and serotonergic mechanisms [16]. Furthermore, vlPAG coordinates the functional correlation between breathing pattern and fear-related behavioral responses, which are essential for survival. This neuronal circuit may constitute a key limbic system-related component, linking respiratory signals with behavioral responses to threat [23], which is highly correlated to anxiety disorders. Thus, vlPAG is a potential target structure for the treatment of anxiety disorder related to breathing pattern abnormalities.

Author contribution G. H. de Mello Rosa, F. Ullah, Y. B. de Paiva, J. A. da Silva, and P. Medeiros performed the experiments, analyzed and interpreted the data, and wrote the manuscript. L. G. S. Branco, A. P. Corrado, N. C., Coimbra and A. F. Biagini designed the experiments, analyzed and interpreted the data, and wrote the manuscript. All authors have approved the final version of manuscript.

Funding This work was supported by National Council of Scientific and Technological Development (CNPq) (grants 483763/2010–1 and 474853/2013–6), São Paulo Research Foundation (FAPESP) (grants 2009/54014–7, 2016/18218–0, and 2016/17081–9), and a Pro-Rectory of the University of São Paulo (USP) Research Grant (NAP-USP-NuPNE; process 1Aq2012-156-USP-12.1.25440.01.6). G. H. de Mello Rosa was a Magister Scientiae (M.Sc.) student supported by CNPq.
(M.Sc. process 134564/0), A. F. Biagioni was supported by FAPESP (process 2014/10742-7 and Research and Innovation Programme under Grant Agreement numbers GrapheneCore2 (785219) and Graphene-Core3 (881603) for post-doctorate. F. Ullah was supported by the Academy of Sciences for the Developing World (TWAS)-CNPq (Sc.D. Fellowship process 190316/2010–1). J. A. Silva was a recipient of post-doctoral fellowships (FAPESP 2015/10313–1, and Neurologia-PNPD-CAPES-001 Post-doctoral processes). Y. B. de Paiva was supported by CAPES (Sc.D. fellowship process CAPES/PROEX 33002029012P3; grant 001). N. C. Coimbra was granted a research fellowship (level 1A) from CNPq (processes 301905/2010–0 and 301341/2015–0); F. Mederiso was a recipient of post-doctoral fellowships from FAPESP (2017/13560–5) and CNPq (150806/2021–3). The authors are grateful to D. H. Elias-Filho for providing expert technical assistance. D. H. Elias-Filho received a technician scholarship from FAPESP (TT-2, process 02/01497–1) and was the recipient of scholarships sponsored by CNPq (processes 501858/2005–9, 500896/2008–9, and 505461/2010–2).

Availability of data and material Data will be made available on request.

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bartlett D, Tenney SM (1970) Control of breathing in experimental anemia. Respir Physiol 10:384–395. https://doi.org/10.1016/0034-5687(70)90050-3
2. Biagioni AF, De Freitas RL, Da Silva JA, De Oliveira RC, De Oliveira R, Alves VM, Coimbra NC (2013) Serotonergic neural links from the dorsal raphe nucleus modulate defensive behaviors organised by the dorsomedial hypothalamus and the elaboration of fear-induced antinociception via locus coeruleus pathways. Neuropsychopharmacology 67:379–394. https://doi.org/10.1016/j.neuropharm.2012.10.024
3. Biagioni AF, de Oliveira RC, de Oliveira R, da Silva JA, dos Anjos-Garcia T, Roncon CM, Corrado AP, Zangrossi H Jr, Coimbra NC (2016) 5-Hydroxytryptamine 1A receptors in the dorsomedial hypothalamus connected to dorsal raphe nucleus inputs modulate defensive behaviours and mediate innate fear-induced antinociception. Eur Neuropsychopharmacol 26:532–545. https://doi.org/10.1016/j.euroneuro.2015.12.032
4. Bittencourt AS, Carobrez AP, Zampregno LP, Tušk S, Schenberg LC (2004) Organization of single components of defensive behaviors within distinct columns of periaqueductal gray matter of the rat: role of N-methyl-D-aspartic acid glutamate receptors.
Pflügers Archiv - European Journal of Physiology (2022) 474:469–480

19. Fanselow MS (1994) Neural organization of the defensive behavior system responsible for fear. Psychon Bull Rev 1:429–438. https://doi.org/10.3755/BF03210947

20. Faul L, Stjepanovic D, Stivers JM, Stewart GW, Graner JL, Morey RA, LaBar KS (2020) Proximal threats promote enhanced acquisition and persistence of reactive fear-learning circuits. Proc Natl Acad Sci U S A 117:16,678–16,689. https://doi.org/10.1073/pnas.2004258117

21. Faulk OK, Pattinson KTS (2017) The cortical connectivity of the periaqueductal gray and the conditioned response to the threat of breathlessness. Elife 6:1–18. https://doi.org/10.7554/eLife.21749

22. Faulk OK, Jenkinson M, Ezra M, Pattinson KTS (2016) Conditioned respiratory threat in the subdivisions of the human periaqueductal gray. Elife 5:1–19. https://doi.org/10.7554/eLife.12047

23. Faull OK, Subramanian HH, Ezra M, Pattinson KTS (2019) The midbrain periaqueductal gray as an integrative and interoceptive neural structure for breathing. Neurosci Biobehav Rev 98:135–144. https://doi.org/10.1016/j.neubiorev.2018.12.020

24. Holstege G, Beers CM, Subramanian HH (2014) The periaqueductal gray controls brainstem emotional motor systems including respiration. Prog Brain Res 209:379–405. https://doi.org/10.1016/B978-0-444-63274-6.00020-5

25. Harricharan S, Rabellino D, Frewen PA, Densmore M, Thébèrge J, McKinnon MC, Schore AN, Lanius RA (2016) fMRI functional connectivity of the periaqueductal gray in PTSD and its dissociative subtype. Brain Behav 6:1–16. https://doi.org/10.1002/brb3.579

26. Holstege G (1991) Descending pathways from the periaqueductal gray and adjacent areas. NATO ASI Ser (Series A Life Sci 213:Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3302-3

27. Kavaliers M (1988) Brief exposure to a natural predator, the short-tailed weasel, induces benzodiazepine-sensitive analgesia in white-footed mice. Physiol Behav 43:187–193. https://doi.org/10.1016/0031-9384(88)90236-3

28. Khan AU, Falconi-Sobrinho LL, dos Anjos-Garcia T, de Fátima de Freitas RL, de Freitas JPC, Laure CJ, Coimbra NC (2018) The rodent-versus-wild snake paradigm as a model for studying anxiety- and panic-like behaviors: face, construct and predictive validities. Neuroscience 369:336–349. https://doi.org/10.1016/j.neuroscience.2017.11.031

29. Koutsikou S, Watson TC, Fanselow MS (1990) Cats produce analgesia in rats in response to exposure to a cat. Neurosci Biobehav Rev 14:319–326. https://doi.org/10.1016/0167-8760(90)90066-9

30. Lester LS, Fanselow MS (1985) Exposure to a cat produces opioid analgesia in rats. Behav Neurosci 99:756–759. https://doi.org/10.1037/0735-7044.99.4.756

31. Lichtman AH, Fanselow MS (1990) Cats produce analgesia in rats on the tail-flick test: naltrexone sensitivity is determined by the nociceptive test stimulus. Brain Res 533:91–94. https://doi.org/10.1016/0006-8993(90)91808-V

32. Lovick T, Bandler R (2005) The organization of the midbrain periaqueductal grey and the integration of pain behaviours. Neurobiol Pain (Molecular Cell Neurobiol Oxford: Ox. https://doi.org/10.1093/apophso/978198515616.003.0011

33. Malan A (1973) Ventilation measured by body plethysmography in hibernating mammals and in poikilothersms. Respir Physiol 17:32–44. https://doi.org/10.1016/0034-5687(73)90108-4

34. Morgan MM, Carrive P (2001) Activation of the ventrolateral periaqueductal gray reduces locomotion but not mean arterial pressure in awake, freely moving rats. Neuroscience 102:905–910. https://doi.org/10.1016/S0306-4522(00)00513-3

35. Morgan MM, Whitney PK, Gold MS (1998) Immobility and flight associated with antinociception produced by activation of the ventral and lateral/dorsal regions of the rat periaqueductal gray. Brain Res 804:159–166. https://doi.org/10.1016/S0006-8993(98)00669-6

36. Nunes-de-Souza RL, Miguel TT, Gomes KS, Fugimoto JS, Mendes-Gomes J, Amaral VCS, de Carvalho-Netto EF (2010) Effect of nitric oxide in the periaqueductal gray in defensive behavior in mice: influence of prior local N-methyl-D-aspartate receptor activation and aversive condition. Psychol Neurosci 3:59–66. https://doi.org/10.3922/j.psns.2010.1.007

37. Paschoalin-Maurin T, dos Anjos-Garcia T, Falconi-Sobrinho LL, de Freitas RL, Coimbra JPC, Coimbra NC (2018) The rodent-versus-wild snake paradigm as a model for studying anxiety- and panic-like behaviors: face, construct and predictive validities. Neuroscience 369:336–349. https://doi.org/10.1016/j.neuroscience.2017.11.031

38. Paxinos G, Watson CR (2007) The rat brain in stereotaxic coordinates, 6th edn. Elsevier Academic Press, San Diego

39. Roelofs K (2017) Freeze for action: neurobiological mechanisms in animal and human freezing. Philos Trans R Soc B Biol Sci 372. https://doi.org/10.1098/rspb.2016.0206

40. Sabino JPI, de Oliveira M, Giusti H, Glass ML, Salgado HC, Fazan R (2013) Hemodynamic and ventilatory response to different levels of hypoxia and hypercapnia in carotid body-denervated rats. Clinics 68:395–399. https://doi.org/10.6061/clinics/2013(03)OA18

41. Sabino JPI, da Silva AL, Restel LB, Antunes-Rodrigues J, Glass ML, Branco LGS (2014) Effect of chronic ethanol exposure on rat ventilatory responses to hypoxia and hypercapnia. Clinics 69:360–366. https://doi.org/10.6061/clinics/2014(05)11

42. Subramanian HH (2013) Descending control of the respiratory neuronal network by the midbrain periaqueductal gray in the rat in vivo. J Physiol 591:109–122. https://doi.org/10.1113/jphysiol.2012.245217

43. Subramanian HH, Holstege G (2013) Stimulation of the midbrain periaqueductal gray modulates preinspiratory neurons in the ventrolateral medulla in the rat in vivo. J Comp Neurol 521:3083–3098. https://doi.org/10.1002/cne.23334

44. Subramanian HH, Balnave RJ, Holstege G (2008) The midbrain periaqueductal gray control of respiration. J Neurosci 28:12274–12283. https://doi.org/10.1523/JNEUROSCI.4168-08.2008

45. Tovote P, Esposito MS, Botta P, Chaudun F, Fadok JP, Markovic M, Wolff SBE, Ramakrishnan C, Fennlo L, Deisseroth K, Henry C, Arber S, Lüthi A (2016) Midbrain circuits for defensive behaviour. Nature 534:206–212. https://doi.org/10.1038/nature17996

46. Uribe-Marío A, Francisco A, Castiblanco-Rocha MA, Twadrowsky A, Salgado-Rohner CJ, Crippa JAS, Hallak JEC, Zuardi AW, Coimbra NC (2012) Anti-aversive effects of cannabinoid on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 37:412–421. https://doi.org/10.1038/npp.2011.188

47. Vaaga CE, Brown ST, Ramani IM (2020) Cerebellar modulation of synaptic input to freezing-related neurons in the periaqueductal gray. Elife 9:1–28. https://doi.org/10.7554/eLife.54302

48. Vianna DML, Landeira-Fernandez J, Brandão ML (2001) Dysautonomic control of respiration in hibernating mammals and in poikilotherms. Respir Physiol 17:32–44. https://doi.org/10.1016/S0034-5687(01)00052-5
49. Walker P, Carrive P (2003) Role of ventrolateral periaqueductal gray neurons in the behavioral and cardiovascular responses to contextual conditioned fear and poststress recovery. Neuroscience 116:897–912. https://doi.org/10.1016/S0306-4522(02)00744-3

50. Watson TC, Cerminara NL, Lumb BM, Apps R (2016) Neural correlates of fear in the periaqueductal gray. J Neurosci 36:12,707–12,719. https://doi.org/10.1523/JNEUROSCI.1100-16.2016

51. Wright KM, McDannald MA (2019) Ventrolateral periaqueductal gray neurons prioritize threat probability over fear output. Elife 8:1–28. https://doi.org/10.7554/eLife.45013

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.